摘要
目的探讨使用华法林抗凝治疗对合并心脏瓣膜病孕妇及胎儿的影响。方法选择2005年10月至2014年10月78例合并心脏瓣膜病妊娠妇女进行抗凝治疗。随机分为A、B两组，A组44例患者全程采用口服国产华法林抗凝治疗，B组34例患者采用华法林与低分子肝素交替抗凝治疗。比较两组患者的妊娠结局。结果两组妊娠期间均无严重栓塞并发症；两组患者妊娠强化心功能变化情况、死胎、流产、产后大出血、新生儿窒息、新生儿畸形、新生儿低体质量等指标比较差异也未见统计学意义（P均〉0．05）。结论合并心脏瓣膜病的妇女在妊娠期间单一服用小剂量华法林（〈5mg/d）为一种相对安全有效的抗凝治疗。
Objective To investigate the effect of warfarin anticoagulant therapy on pregnant women with valvular heart disease and fetus. Methods Seventy-eight cases of pregnant women with valvular heart disease in our hospital from October 2014 to October 2005 were treated with anticoagulant therapy. Patients were randomly divided into group A and group B. Patients received full warfarin therapy in group A （ n = 44） and low molecular weight heparin and warfarin alternative therapy in group B （ n = 34）. The pregnancy outcomes of two groups were compared. Results No severe complications of embolism were observed in the two groups of patients during pregnancy. There was no significant differences in terms ot cardiac function changes, stillbirth, abortion, postpartum hemorrhage, neonatal asphyxia, neonatal malformations and low birth weight indicators between the two groups （ P 〉 0.05 ）. Conclusions Low-dose warfarin （less than 5 mg/d） is a safe and effective anticoagulant therapy for patients with valvular heart disease during pregnancy.
出处
《中国实用医刊》
2016年第11期22-24,共3页
Chinese Journal of Practical Medicine
关键词
华法林
抗凝
妊娠
心脏瓣膜病
Warfarin
Anticoagulation
Pregnancy
Valvular heart disease
